Newron has announced receipt of regulatory clearance to conduct its Phase III programme for evenamide (ENIGMA-TRS), taking it one step closer to the market. It will comprise two separate trials: ENIGMA-TRS 1, a 600-patient international study with enrolment set to start imminently; and ENIGMA-TRS 2
